Evidence map›Paper›PMID 42698444›Full record

ArticleFrontiers in oncology2026

Prognostic impact of CD123 overexpression on the outcome of pediatric acute myeloid leukemia.

Mona Mohammed, Iman Sidhom, Nahla El-Sharkawy, Mahmoud Hammad, Maram Salama, Sonia Soliman, Dina Yassin, Sherine Salem, Nayera Hamdy, Amr Elnashar and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mona Mohammed *Department of Pediatric Oncology, Children's Cancer Hospital Egypt, Cairo, Egypt.
Iman Sidhom *Department of Pediatric Oncology, National Cancer Institute, Cairo University, and Children's Cancer Hospital Egypt, Cairo, Egypt.
Nahla El-SharkawyDepartment of Clinical Pathology Children's Cancer Hospital Egypt and National Cancer Institute, Cairo University, Cairo, Egypt.
Mahmoud HammadDepartment of Pediatric Oncology, National Cancer Institute, Cairo University, Cairo, Egypt.
Maram SalamaDepartment of Pediatric Oncology, Children's Cancer Hospital Egypt, Cairo, Egypt.
Sonia SolimanDepartment of Clinical Pathology Children's Cancer Hospital Egypt and National Cancer Institute, Cairo University, Cairo, Egypt.
Dina YassinDepartment of Clinical Pathology Children's Cancer Hospital Egypt and National Cancer Institute, Cairo University, Cairo, Egypt.
Sherine SalemDepartment of Clinical Pathology Children's Cancer Hospital Egypt and National Cancer Institute, Cairo University, Cairo, Egypt.
Nayera HamdyDepartment of Clinical Pathology Children's Cancer Hospital Egypt and National Cancer Institute, Cairo University, Cairo, Egypt.
Amr ElnasharDepartment of Clinical Research, Children's Cancer Hospital Egypt, Cairo, Egypt.
Sherif AbouelnagaDepartment of Pediatric Oncology, National Cancer Institute, Cairo University, and Children's Cancer Hospital Egypt, Cairo, Egypt.
Sonia AhmedDepartment of Pediatric Oncology, National Cancer Institute, Cairo University, and Children's Cancer Hospital Egypt, Cairo, Egypt.
Ahmed ElhemalyDepartment of Pediatric Oncology, National Cancer Institute, Cairo University, and Children's Cancer Hospital Egypt, Cairo, Egypt.
Alaa ElhaddadDepartment of Pediatric Oncology, National Cancer Institute, Cairo University, and Children's Cancer Hospital Egypt, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: Despite advances in acute myeloid leukemia (AML) therapy, outcomes remain poor. CD123 overexpression influences proliferation and enhanced survival of leukemic cells. Its impact on the outcome is still debatable. This study aimed to assess CD123 overexpression frequency in pediatric AML, its relation with disease features, and its impact on outcomes. Methods: This retrospective study included pediatric patients with Results: Among 403 patients, 141 (35%) were CD123 Conclusions: The association of CD123

Indexed as

acute myeloid leukemiaCD123 expressionCD123 immunophenotypingIL-3 receptor α chainpediatrics

Identifiers

PMID42698444
PMCPMC13541458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.